Global Experts from 23 Countries Convene in Barcelona to Confront Rising Rates of Early Onset Colorectal Cancer
Springfield, Mo., May 27, 2025 (GLOBE NEWSWIRE) -- Fight Colorectal Cancer (Fight CRC), in partnership with Dr. José Perea of the Instituto de Investigación Biomédica de Salamanca (IBSAL) and a global network of collaborators, will host the inaugural Global Early Onset Colorectal Cancer Think Tank (GEOCRCTT) on June 18–19 in Barcelona, Spain. This two-day event will convene leading experts from research, healthcare, and advocacy to develop a comprehensive research strategy aimed at reversing the troubling trend in early onset colorectal cancer (EOCRC) cases.
'It's the first time we've ever hosted an international meeting, and we are thrilled to convene more than 75 scientists and patients,' said Anjee Davis, CEO of Fight CRC. 'Global partners consistently ask us, 'How can we meaningfully engage patients and reflect their voices in the science?' Through this international coalition of scientists, we're committed to advancing the science with patients at the center. We want to make sure the lessons we've learned in the U.S. are shared globally. This isn't just about presenting research; it's about rolling up our sleeves and working together to drive it forward. It's a true dialogue around collaboration, and that level of global partnership simply hasn't happened before.'
As early onset colorectal cancer becomes increasingly prevalent, especially in countries with traditionally lower risk, the GEOCRCTT represents a timely and necessary response. Through keynote speeches, interactive panel discussions, and specialized breakout sessions, the Think Tank will facilitate knowledge sharing across borders and disciplines. Experts will focus on setting research priorities, strengthening collaborative efforts, and identifying targeted ways to support patients, caregivers, and affected communities worldwide.
'This gathering marks a pivotal moment in our approach to early onset colorectal cancer research as one of the only initiatives to explore global etiology; not just from a specific country or region, the entire world,' said Andrea (Andi) Dwyer, advisor to Fight CRC and member of the University of Colorado Cancer Center. "The future of EOCRC research and patient support depends on this level of unity and commitment.'
The GEOCRCTT reflects the growing urgency to address EOCRC with a united, strategic approach. For more information on the GEOCRCTT, or to support Fight Colorectal Cancer and its partners, visit fightcolorectalcancer.org or join the conversation at #GEOCRCTT.
GEOCRCTT Goals and Deliverables:
Publishing Think Tank Outcomes: Findings, recommendations, and action items will be published in a leading peer-reviewed journal, making them accessible to the global research and medical communities.
Supporting Critical Research Efforts: Through GEOCRCTT, six grants have been awarded to support baseline data collection internationally. This research funding underscores a united commitment to filling gaps in understanding EOCRC's causes, risk factors, and trends on an international scale.
Empowering Patients and Advocates: Through focused sessions, GEOCRCTT will provide advocacy groups and patient communities with the latest information and strategies to elevate awareness and improve support networks globally. Fight CRC remains committed to advancing these efforts and fostering a global culture of informed, patient-centered care.
Attachment
Global Early Onset Colorectal Cancer Think Tank
CONTACT: Savanna Doud Fight Colorectal Cancer 703-548-1225 media@fightcrc.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
In Vitro Diagnostics Market Size to Exceed USD 132.18 Bn by 2034
According to Precedence Research, the global in vitro diagnostics (IVD) market size is expected to exceed USD 132.07 billion by 2034, increasing from USD 104.01 billion in 2025, with a CAGR of 2.30% between 2025 and 2034. Growth is fueled by rising chronic disease prevalence, demand for early detection, and rapid adoption of advanced molecular testing technologies. Ottawa, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The worldwide in vitro diagnostics market size accounted for USD 102.05 billion in 2024, and is predicted to grow from USD 104.01 billion in 2025 to approximately USD 132.07 billion by 2034. The growing awareness about the early detection of diseases and the growing prevalence of chronic diseases drive market growth. Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for Before You Buy – Get the Sample Report@ In Vitro Diagnostics Industry – Strategic Insights In terms of revenue, the in vitro diagnostics market has been calculated at USD 104.01 billion in 2025. It is anticipated to reach over USD 132.07 billion by 2034. North America captured a 42% revenue share of the global market in 2024. Asia Pacific is expected to grow at a significant CAGR between 2025 and 2034. By product, the reagents segment held the major market share of 66.07% in 2024. By product, the instruments segment is expanding at a solid CAGR from 2025 to 2034. By test location, the point-of-care segment held a significant share in 2024. By test location, the home care segment is anticipated to witness considerable growth from 2025 to 2034 By technology, the molecular diagnostics segment contributed the largest market share of 33.06% in 2024. By technology, the immunoassay segment is projected to grow at a considerable CAGR from 2025 to 2034. By application, the infectious disease segment accounted for the biggest market share of 52.53% in 2024. By application, the oncology segment is growing at a notable CAGR between 2025 and 2034. By end user, the hospital segment held the largest market share of 37.89% in 2024. In Vitro Diagnostics Market Revenue (USD Million) By Product Type 2022-2024 Product 2022 2023 2024 Instruments 28,950.5 26,909.55 25,379.75 Reagents 75,883.9 70,996.28 67,404.76 Services 10,654.3 9,861.36 9,264.58 In Vitro Diagnostics Market Revenue (USD Million) By Technology 2022-2024 Technology 2022 2023 2024 Immunoassay 34,688.2 32,433.72 30,774.22 Hematology 6,827.4 6,345.41 5,984.69 Clinical Chemistry 20,236.7 18,978.14 18,061.02 Molecular Diagnosis 38,255.7 35,662.26 33,736.25 Coagulation 4,680.5 4,328.27 4,061.72 Microbiology 6,384.9 5,916.29 5,563.15 Others 4,415.3 4,103.12 3,868.03 In Vitro Diagnostics Market Revenue (USD Million) By Application 2022-2024 Application 2022 2023 2024 Infectious Diseases 61,149.9 56,833.27 53,602.44 Diabetes 9,146.6 8,475.36 7,969.48 Oncology 8,727.7 8,323.38 8,055.14 Cardiology 9,104.3 8,538.03 8,125.43 Nephrology 6,633.3 6,127.88 5,744.71 Autoimmune Diseases 5,350.6 4,987.83 4,718.45 Drug Testing 3,986.6 3,757.30 3,593.52 Others 11,389.6 10,724.14 10,239.92 Available for Instant Download – Order This Premium Market Study Today@ In Vitro Diagnostics Market Overview In vitro diagnostics (IVD) are tests conducted on samples retrieved from human bodily tissues and fluids. IVD performs on biological samples like tissue, blood, urine, and others, and tests are performed in the laboratory. Tests help to diagnose various infections, diseases, & other health issues, and monitor patient health. IVD helps in the early detection of diseases, avoids the spreading of diseases, and enhances patient care. The common IVD tests are COVID-19, HIV tests, pregnancy tests, blood glucose monitoring, and many more. Factors like a rise in personalised medicines, increasing awareness about the early detection of diseases, growing cardiovascular diseases, and technological advancements in IVD contribute to the in vitro diagnostics market. Top Types of IVD Technologies in 2025: Technology Working Principle Uses ELISA Capturing the antigen-antibody reaction Autoimmune disorder HIV Lyme Disease NGS DNA fragmentation and parallel sequencing Cancer Genetic disorders Infectious diseases CLIA The binding antibody and the corresponding antigenChemiluminescence reactions Hormone imbalances Tumor detection Diabetes Hypertension PCR/RT-PCR Amplification of DNA & RNA Genetic disorder Infectious diseases Flow Cytometry Laser-based techniques for the analysis of cells Blood disorders Immune system problems Myelodysplastic syndromes Lateral Flow Sample amplification and target binding Pregnancy Respiratory infections Mosquito-borne diseases Sexually transmitted infections ➤ In Vitro Diagnostics Market Major Trends: Advanced Lateral Flow Tests (LFTs) Beyond COVID-19Evolved LFTs are now capable of detecting a wide array of substances—from vitamin D and iron to stroke markers—using novel samples like fingerprint sweat or pet vomit. Their versatility is rapidly expanding across healthcare, environmental, and even animal diagnostics. Integrated Point-of-Care and At-Home Nutritional DiagnosticsInnovations like smartphone-compatible devices (e.g., Cornell's NutriPhone) can measure iron, vitamin A, D, and B12 from just a finger-prick in minutes—indicating a shift toward compact, multipurpose diagnostics useful in both clinics and homes. Artificial Intelligence–Enhanced Digital Nucleic Acid Amplification (dNAAT)Cutting-edge techniques such as digital PCR (dPCR) and digital LAMP (dLAMP), combined with AI-powered image analysis, are enhancing diagnostic precision and sensitivity. These advancements pave the way for scalable, faster, and more accurate molecular testing, even at the point of care. In Vitro Diagnostics Market Opportunity What is the Opportunity for the In Vitro Diagnostics Market? The growing prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases increases demand for in vitro diagnostics for early detection of diseases. The increasing patient demand for early detection of chronic diseases increases demand for IVD tests. The increasing demand for tracking the progression of chronic diseases increases the adoption of IVD for managing disease effectively and adjusting treatment plans. The increasing development of personalised treatment requires IVD technologies. The availability of point-of-care testing increases adoption of IVD for efficient management of chronic conditions. The increasing awareness of early disease detection and the increasing demand for regular health check-ups increase the adoption of IVD. The growing prevalence of chronic diseases creates an opportunity for the growth of the in vitro diagnostics market. In Vitro Diagnostics Market Challenges and Limitations and Challenges: Why High Development Cost Limitation for the In Vitro Diagnostics Market? Despite several benefits of in vitro diagnostics in various disease diagnoses, the high development cost restricts the market growth. Factors like the need for extensive clinical validation, the complex nature of IVD platforms, stricter regulation, high investment in R&D, and intensive clinical trials are responsible for high development costs. The need for high investment in personnel, equipment, and reagents directly affects the market. The complexity of IVD technologies and lengthy development cycles increases the production costs. The stricter regulations for the development of IVD tests require a high cost. The need for extensive compliance, documentation, and quality assurance requires a high cost. The requirement of specialized materials and precision manufacturing increases the production cost. The high development cost hampers the growth of the in vitro diagnostics market. Scope of the In Vitro Diagnostics Market Report Attributes Key Statistics Market Size in 2025 USD 104.10 Billion Market Size in 2030 USD 117.18 Billion Market Size in 2032 USD 124.66 Billion Market Size by 2034 USD 132.07 Billion Growth Rate 2025-2034 CAGR of 2.30% Base Year 2024 Forecast Period 2025 to 2034 Historical Data 2021 to 2023 Largest Regional Market (2024) North America – 42% revenue share Fastest Growing Regional Market Asia Pacific Segments Covered Product, Technology, Application and Regions Regions Covered North America, APAC, Europe, Latin America, MEAN, Rest of the World Key Players Covered Alere, Inc., Hoffmann-La Roche Ltd., Arkray,Beckman Coulter, Becton Disckinson, Bio-Rad laboratories, Danaher, Sysmex Corporation, Abbott Laboratories and other ➡️ Become a valued research partner with us ☎ How Big is the U.S. In Vitro Diagnostics (IVD) Market? According to Precedence Research, the U.S. in vitro diagnostics (IVD) market size was evaluated at USD 34.98 billion in 2024 and is expected to rise from USD 35.43 billion in 2025 to approximately USD 42.55 billion by 2034, at a CAGR of 2.20% from 2025 to 2034. The Complete Study is Immediately Accessible | Download the Sample Pages of this Report@ U.S. In Vitro Diagnostics Market Key Takeaways The U.S. in vitro diagnostics market reached USD 34.98 billion in 2024. It is projected to hit around USD 42.63 billion by 2034. The market is growing at a CAGR of 2% from 2025 to 2034. By product, the reagents segment held the highest share of 67% in 2024. By test location, the point-of-care segment dominated the market in 2024. By technology, the Immunoassay segment is expected to grow at a significant CAGR from 2025 to 2034. By application, the infectious diseases segment dominated the market with the biggest market share in 2024. By application, the oncology segment is expected to witness the fastest CAGR of growth during the forecast period of 2025-2034. By end user, the hospital segment held the dominating share of the market in 2024. U.S. In Vitro Diagnostics Market Leading Companies Alere, Inc. Beckman Coulter BD Bio-Rad laboratories Danaher Abbott Laboratories Thermo Fisher Scientific Inc. bioMérieux, Inc Quest Diagnostics Illumina, Inc. Get Immediate Access – Secure Your Copy of This Premium Research Report@ Which Region Dominated the In Vitro Diagnostics Market? North America dominated the in vitro diagnostics market in 2024. The well-established healthcare infrastructure, like research centers, modern clinical laboratories, and hospitals, increases the adoption of IVD. The ongoing technological innovations like digital health integration, high-throughput systems, and lab-on-a-chip equipment in IVD help the market growth. The increasing prevalence of infectious and chronic diseases increases the adoption of IVD. The increasing healthcare spending and focus on personalised medicine increase the adoption of IVD. The presence of major players like BD, Abbott, and Thermo Fisher Scientific drives the market growth. Why Asia Pacific Experiencing the Fastest Growth in the In Vitro Diagnostics Market? Asia Pacific is experiencing the fastest growth in the market during the forecast period. The growing prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases increases the adoption of IVD. The growing government investment in healthcare infrastructure and increasing spending on diagnostics increases demand for IVD, helping the market growth. The increasing awareness about the early detection of diseases and the growing expansion of healthcare facilities like clinics & hospitals increases adoption of IVD, supporting the overall growth of the market. 'The integration of AI with molecular diagnostics will reshape IVD workflows over the next decade, improving test turnaround times and accuracy, particularly in decentralized settings,' said Deepa Pandey, Principal Consultant at Precedence Research. In Vitro Diagnostics Market Segmentation Analysis: Product Analysis: Why did Reagent Segment Dominate the In Vitro Diagnostics Market? The reagent segment dominated the in vitro diagnostics market in 2024. The compatibility of reagents with various diagnostics platforms, like point-of-care, clinical laboratories, and hospitals, helps the market growth. The growth in personalised medicine increases the adoption of reagents. The growth in diagnostics like oncology, infectious diseases, and chronic diseases increases the adoption of reagents. The growing utilization of molecular diagnostic techniques increases demand for reagents, driving the overall growth of the market. The instruments segment is the fastest-growing in the market during the forecast period. The growing prevalence of chronic diseases like cardiovascular conditions, diabetes, and cancer increases demand for instruments for early detection. The increasing focus on early detection of diseases and timely treatment increases demand for instruments. The ongoing innovations in diagnostic technologies and the expansion of point-of-care testing support the market growth. Technology Analysis: How Immunoassay Segment Held the Largest Share in the In Vitro Diagnostics Market? The immunoassay segment held the largest revenue share in the in vitro diagnostics market in 2024. The increasing detection of various analytes like proteins, drugs, hormones, and antibodies increases the adoption of immunoassays. The increasing demand for ELISA and CLIA immunoassays helps the market growth. The increasing demand for POC testing and the increasing availability of central labs increase the adoption of immunoassays. The increasing risks of infectious diseases and chronic diseases increase demand for immunoassay-based diagnosis, driving the overall market growth. The molecular diagnostics segment is experiencing the fastest growth in the market during the forecast period. The growing utilization of techniques like next-generation sequencing & PCR for early disease diagnosis helps the market growth. The increased spread of infectious diseases increases the adoption of molecular diagnostics to control the spread of disease. The increasing development of personalised medicine and growth in at-home testing & point-of-care fuels demand for molecular diagnostics, supporting the overall market growth. Application Analysis: Which Application Segment Dominated the In Vitro Diagnostics Market? The oncology segment dominated the in vitro diagnostics market in 2024. The increasing prevalence of cancer increases demand for IVD for accurate diagnosis and early detection of conditions. The ongoing advancements in molecular diagnostics, like liquid biopsies and next-generation sequencing, help in the market growth. The increasing demand for early detection of cancer and the growth in the development of personalised medicines increases the demand for IVD. The increasing demand for IVD tests for various cancers like lung, prostate cancers, breast cancers, and colorectal drives the market growth. The infectious disease segment is the fastest-growing in the market during the forecast period. The growth in infectious diseases like viral outbreaks, respiratory infections, and STDs increases demand for IVD. The increasing awareness about the early detection of infectious diseases and focus on reducing transmission increases the adoption of IVD. The increasing prevalence of hepatitis, HIV, and tuberculosis increases demand for IVD, supporting the overall market growth. Test Location Analysis: How Point of Care Segment Held the Largest Share in the In Vitro Diagnostics Market? The point of care segment held the largest revenue share in the in vitro diagnostics market in 2024. The increasing demand for faster test results and focus on reducing turnaround times increases the adoption of point of care. The increasing need for IVD tests in underserved and remote areas increases the adoption of IVD. The focus on the management of chronic conditions like cardiovascular diseases and diabetes increases demand for POC. The increasing suitability of POC in various settings like doctors' offices, hospitals, and clinics drives the market growth. The home care segment is experiencing the fastest growth in the market during the forecast period. The growing patients' preference for testing at home and the growing expansion of home-based testing help the market growth. The increasing development of automated, user-friendly, and portable IVD devices increases adoption of care. The increasing management of chronic conditions like cardiovascular diseases & diabetes increases demand for home care, supporting the overall growth of the market. End User Analysis: Why did the Hospital Segment Dominate the In Vitro Diagnostics Market? The hospitals segment dominated the in vitro diagnostics market in 2024. The high availability of a wide range of diagnostic tests and the increasing number of patients increase the adoption of hospitals. The growing demand for accurate and early diagnosis of diseases increases the demand for hospitals. The availability of advanced technologies like molecular diagnostic tools, automated analyzers, and others helps the market growth. The presence of trained personnel, well-established infrastructure, and high-quality equipment in hospitals drives the market growth. Related Topics You May Find Useful: ➢ In-Vitro Inflammatory Bowel Disease Diagnostics Market: Uncover how biomarker innovations are transforming early IBD detection ➢ Infectious Disease In-Vitro Diagnostics Market: Explore rising demand for rapid pathogen testing and accuracy-driven diagnostics ➢ In-Vitro Diagnostics Enzymes Market: See how enzyme-based assays are becoming indispensable in chronic disease detection ➢ Diagnostic Testing Market: Track how expanding cardiology testing and hospital-led diagnostics are reshaping global healthcare ➢ Next-Generation IVD Market: Dive into how AI, genomics, and precision medicine are redefining diagnostic frontiers ➢ Cancer IVD Market: Analyze how early cancer detection and immunoassays are fueling a surge in diagnostic innovation ➢ Cancer Diagnostics Market: Discover how hospital-led screening and consumables-led solutions are doubling market size by 2034 ➢ DNA Diagnostics Market: Explore how PCR tech and oncology testing are powering DNA testing's rapid growth ➢ IVD Contract Manufacturing Market: Understand how outsourcing efficiencies and consumable demand are driving diagnostic scale-up ➢ In-Vitro Colorectal Cancer Screening Tests Market: Track rising demand for non-invasive CRC screening and lab-based diagnostics In Vitro Diagnostics Market Top Companies Alere, Inc. Hoffmann-La Roche Ltd. Arkray Beckman Coulter Becton Dickinson Bio-Rad Laboratories Danaher Sysmex Corporation Abbott Laboratories Recent Developments: In August 2024, InBios launched an in vitro diagnostic test, a serological ELISA kit for strongyloidiasis. The kit provides results under 75 minutes and is intended for use only in patients with symptoms, clinical history, and signs. (Source: In June 2023, GenWorks Health launched IVD tests for malaria & dengue. The test kits include iScreen Dengue NS1 and iScreen Malaria Card Antigen. The IVD products aim to diagnose, treat, prevent, and cure seasonal diseases. (Source: In September 2023, NeoDx Biotech launched an IVD kit, the HLA-B27 RT-PCR kit for detecting autoimmune disorders. The kits help to analyze disorders like psoriasis, reactive arthritis, ankylosing spondylitis, and inflammatory bowel syndrome. (Source: Case Study: AI-Powered Molecular Diagnostics at Sunrise Labs Boosts Cancer Detection Rates Sunrise Labs, a leading diagnostic center network in Southeast Asia, faced challenges in delivering early, accurate cancer diagnoses to patients in semi-urban and rural areas. Traditional lab workflows required samples to be shipped to centralized facilities, causing delays of 3–5 days before results reached clinicians. Solution Implemented: In 2023, Sunrise Labs partnered with a global IVD leader to deploy a portable, AI-enhanced molecular diagnostics platform capable of running PCR-based oncology tests on-site. The system integrated with the lab's electronic health record (EHR) system, enabling seamless data transfer and analysis. Key Innovations: Point-of-Care Molecular Testing: Allowed oncologists to receive results within 90 minutes. AI-Driven Image Analysis: Improved detection accuracy for early-stage cancers by 18% compared to conventional lab workflows. Custom Reagent Kits: Designed for tropical climates to maintain stability without cold-chain dependency. Results Achieved: Turnaround Time Reduced: From 3–5 days to under 2 hours. Screening Uptake Increased: 35% more patients underwent cancer screening in the first year. Cost Efficiency: Operational costs dropped by 22% due to reduced logistics and sample handling. Patient Outcomes: Early detection rates for breast and cervical cancer improved, enabling earlier treatment interventions. Industry Implication: This case underscores how integrating AI with IVD molecular diagnostics can dramatically improve accessibility and patient outcomes in emerging markets, aligning with broader industry trends toward decentralization and personalized medicine. It also highlights the commercial potential for IVD players to target underserved regions with tailored product designs. In Vitro Diagnostics Market Segments Covered in the Report By Product Reagents Instruments Services By Test Location Point of Care Home Care Others By Technology Immunoassay Instruments Reagents Services Hematology Instruments Reagents Services Clinical Chemistry Instruments Reagents Services Molecular Diagnostics Instruments Reagents Services Coagulation Instruments Reagents Services Microbiology Instruments Reagents Services Others Instruments Reagents Services By Application Diabetes Cardiology Nephrology Infectious Disease Oncology Drug Testing Autoimmune Diseases Others By End User Hospitals Standalone Laboratories Academic & Medical Schools Point-of-Care Others By Region North America U.S. Canada Europe Germany UK France Italy Spain Sweden Denmark Norway Asia Pacific China Japan India South Korea Thailand Latin America Brazil Mexico Argentina Middle East & Africa South Africa UAE Saudi Arabia Kuwait Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as Immediate Delivery Available | Buy This Premium Research Report@ You can place an order or ask any questions, please feel free to contact at sales@ | +1 804 441 9344 Stay Ahead with Precedence Research Subscriptions Unlock exclusive access to powerful market intelligence, real-time data, and forward-looking insights, tailored to your business. From trend tracking to competitive analysis, our subscription plans keep you informed, agile, and ahead of the curve. Browse Our Subscription Plans@ About Us Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. Web: Our Trusted Data Partners: Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor | Market Stats Insight Get Recent News: For the Latest Update Follow Us: LinkedIn | Medium | Facebook | Twitter ✚ Explore More Market Intelligence from Precedence Research: ➡️ In-Vitro Fertilization Market: Explore how technological advances and rising infertility treatments are driving global IVF demand ➡️ Artificial Intelligence Diagnostics Market: See how AI-powered tools are revolutionizing accuracy and speed in clinical diagnostics ➡️ Non-Invasive Cancer Diagnostics Market: Discover how liquid biopsies and imaging innovations are reshaping cancer detection ➡️ Home Diagnostics Market: Track how convenience and digital health integration are fueling at-home testing adoption ➡️ Point-of-Care Diagnostics Market: Understand how rapid testing solutions are transforming care delivery in clinics and beyond ➡️ Infectious Respiratory Disease Diagnostics Market: Analyze demand shifts driven by pandemic preparedness and respiratory health awareness ➡️ Breast Cancer Diagnostics Market: Learn how imaging, biopsy, and AI tools are advancing early breast cancer detection ➡️ Point-of-Care Molecular Diagnostics Market: Explore how portable PCR and molecular tools are enhancing real-time diagnosis ➡️ Rapid Diagnostics Market: See how speed, accuracy, and accessibility are redefining modern diagnostics ➡️ Next-Generation Cancer Diagnostics Market: Discover how genomic profiling and precision oncology are shaping next-gen cancer testing ➡️ Tissue Diagnostics Market: Understand how histopathology innovations are improving disease characterization ➡️ Blood Transfusion Diagnostics Market: Track advances in screening technologies ensuring safer transfusion practices ➡️ Infectious Disease Diagnostics Market: Explore how rising disease outbreaks are accelerating global diagnostic capabilities ➡️ Point-of-Care Infectious Disease Diagnostics Market: See how rapid and mobile solutions are revolutionizing infectious disease management ➡️ DNA Diagnostics Market: Learn how genetic testing is unlocking new frontiers in personalized medicine ➡️ Infectious Disease In-Vitro Diagnostics Market: Discover how innovation in IVD is boosting accuracy in pathogen detectionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
U.S. Pet Supplements Market to Reach US$2.01 Billion by 2033
A humanized approach to pet wellness defines the current market. Owners increasingly choose familiar chewable supplements for preventative care, particularly for joint health in the nation's vast and aging canine population, prioritizing convenience and proactive health. Chicago, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The U.S. pet supplement market was valued at US$ 1,133.1 million in 2024 and is expected to reach US$ 2,014.1 million by 2033, growing at a CAGR of 6.6% during the forecast period 2025–2033. The financial commitment of American pet owners underscores the deep emotional bond they share with their animals. In 2024, it is estimated that over 114 million U.S. households are actively purchasing pet products, creating a vast and engaged consumer base. The value per buyer has reached a significant $782 in 2024, reflecting a willingness to invest in premium goods. On an annual basis, the average cost for dog owners hovers around $1,533, a figure that now routinely includes supplements. Specifically, dog owners allocated approximately $79 for vitamins in 2024, while cat owners spent about $60 on similar products. This spending trend is accelerating; 32% of pet owners reported spending more on their pets in 2024, a notable increase from the 30% reported in 2023. Download Sample Pages: Conversely, only 20% of owners reported a decrease in spending, a marginal increase from 19% in the prior year, indicating that discretionary spending on pet wellness remains robust. Key Findings in US Pet Supplement Market Market Forecast (2033) US$ 2,014.1 million CAGR 6.6% By Pet Dog (57.70%) By Prodcut Type Multivitamins (36.30%) By Specialty Hip & join (27.30%) By Product Form Chewable Tablets (43.30%) By Source Conventional (79.1%) By End User Residential (87.3%) By Distribution Channel Offline (67.1%) By Manufacturing Contract/Outsource (CDMOs) (66.0%) Top Drivers The humanization of pets leads owners to seek human-grade ingredients. A strong veterinary focus on preventative care boosts supplement recommendations. Rising pet ownership among millennials who prioritize their pets' health. Top Trends Demand for personalized supplements based on pet breed, age, genetics. The rapid growth of sustainable and plant-based ingredient formulations. Dominance of e-commerce channels offering subscriptions and direct-to-consumer models. Top Challenges Navigating complex FDA regulations and the need for claims substantiation. Intense market competition and product saturation from numerous new brands. Consumer price sensitivity amidst economic inflation impacting discretionary pet spending. Digital Dominance Reshaping Sales Channels with Unprecedented E-commerce Growth and Success The digital shelf has become the most critical battleground in the US pet supplement market. In 2025, American pet owners are projected to spend a staggering $28.5 billion on pet food and supplies through online channels. This digital migration shows no signs of slowing, with forecasts indicating that U.S. e-commerce in the consumer pet industry will surge to an incredible $60 billion by the year 2030. The ecosystem supporting this growth is vast, comprising 1,861 online businesses dedicated to selling pet food and supplies in the U.S. as of 2024. This channel is particularly effective for specific product formats, with online platforms witnessing a 28% increase in the sales of popular chews and bites in 2024. E-commerce giant Chewy exemplifies this trend, with its Autoship customer sales growing to an impressive $2.23 billion in a recent 2024 quarter. In the first quarter of 2024 alone, Chewy's Autoship segment sales hit $2.2 billion, and its net sales per active customer (NSPAC) climbed to $562, showcasing profound customer loyalty and high lifetime value. Vitamins are a star category online, with 54% of all online pet purchases in 2024 being for these supplements. Younger Generations are Now Defining New Consumer Trends and Directions of the US Pet Supplement Market The future of the pet wellness industry is being shaped by the preferences and purchasing habits of younger consumers. Millennials currently represent the largest demographic of pet owners, accounting for 33% of the total in the U.S. for 2024. Their digital-native behavior is evident in their shopping habits, with 56% of Millennials typically shopping for their pet products online. They are closely followed by Gen Z, 52% of whom also prefer online channels for pet purchases. While slightly less than their younger counterparts, Gen X and Baby Boomers have also embraced e-commerce supporting the US pet supplement market, with 49% and 46% respectively making online purchases for their pets in 2024. Gen Z is also leading the charge in tech adoption, with one in three owners from this generation having purchased a pet tech product in 2024. This affinity for convenience and technology extends to purchasing models, where 61% of Gen Zers and 59% of Millennials are the primary drivers of subscription-based pet purchases in 2024. Pioneering Scientific Breakthroughs and New Product Formulations Redefining Market Standards Innovation is the lifeblood of the modern US pet supplement market, with companies racing to launch products backed by science and formulated for maximum efficacy and convenience. In April 2024, the health and wellness brand Cymbiotika entered the space with a new line of four pet supplements: Probiotic+, Calm, Hip & Joint, and Allergy & Immune Health. Similarly, Fera Pets utilized the SuperZoo 2024 trade show to introduce a new suite of vet-formulated supplements, including a Whole Food Multivitamin and a novel Collagen Plus product. Looking ahead to February 2025, Elanco Animal Health has announced its forthcoming launch of Pet Protect, a comprehensive line of veterinarian-formulated supplements for both dogs and cats. This new line will feature products targeting joint health, multivitamins, Omega-3s, and digestive function, among others. The Wellness Pet Company also unveiled a new Multi-Benefit Supplement for dogs at SUPERZOO 2024, demonstrating the trend toward all-in-one solutions. This product development is increasingly supported by clinical research; a 2024 study demonstrated that a novel postbiotic ingredient can reduce canine itching by 20%, while another study from the same year found a postbiotic powder topper could diminish canine halitosis by an impressive 27%. Veterinarian Endorsements Solidify Consumer Trust and Propel High-Value Product Segment Growth The veterinarian remains one of the most trusted figures in a pet owner's circle of influence, making their recommendations a powerful driver of sales in the US pet supplement market. As of 2024, a significant 74% of veterinarians recommend chews and bites as an effective delivery format for essential nutrients. This professional guidance has a direct impact on purchasing decisions, as seen in 2023 when 36% of dog owners and 28% of cat owners bought joint supplements, often based on direct advice from their veterinarian. Recognizing the importance of this channel, industry players are strengthening their ties to the veterinary community. In a strategic move in May 2024, the veterinary pharmacy Mixlab acquired NexGen Animal Health, an acquisition that immediately expanded its network to 7,000 veterinarians and 55,000 animal owners across thousands of cities. Consequently, the prescribed pet supplements segment is forecast to register the fastest growth rate from 2024 through 2030. This growth is fundamentally supported by an increase in recommendations from vets who are embracing supplements for preventative care protocols. Heightened Regulatory Scrutiny Shapes Market Legitimacy and Ensures Future Consumer Product Safety As the US pet supplement market expands, so does the attention from regulatory bodies intent on protecting consumers and their pets. In 2024, the FDA demonstrated its increasing oversight by issuing warning letters to at least six companies for the illegal sale of unapproved products that contained CBD and/or delta-8 THC. Critically for this sector, at least one of these companies was marketing products specifically for pets. This enforcement action continued into 2025, when on April 7th, the FDA posted additional warning letters to three more pet product companies—House of Alchemy, LLC (operating as CBD Dog Health), Hamet Love, LLC (operating as MycoDog), Bailey's Wellness, LLC (operating as Bailey's CBD), and Holista, LLC (operating as HolistaPet)—for marketing unapproved animal drugs containing CBD and mushroom-based ingredients. Beyond enforcement, the agency is also processing legitimate applications in the US pet supplement market; between October and December 2023, the FDA took action on several new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs), which formally became effective in February 2024. An Omnichannel Approach and Expanding Physical Retail Footprint Are Now Imperative While e-commerce soars, a robust physical retail presence remains crucial for capturing the entire market. In 2024, a remarkable 60% of all pet supplement sales within major retail chains such as PetSmart and Petco were attributed to the popular chews and bites format. Leading brands understand this dual-channel necessity. As of December 31, 2024, the popular brand Zesty Paws had secured placement in more than 18,000 stores, while the established brand Solid Gold was available in over 4,800 stores across the nation. Zesty Paws' distribution network as of 2024 includes retail giants like Costco, Petco, Walmart, Target, PetSmart, and even the pharmacy chain CVS. The physical footprint continues to grow across the US pet supplement market, with Pet Supplies Plus announcing plans to add 50 new stores in 2024 and accelerate that pace to 80 new locations annually from 2025 onwards. Consumer behavior confirms this hybrid reality: in 2024, 51% of pet parents bought pet products online, while 47% made purchases in-store. The most dominant shopping method is omnichannel, with 58% of all pet owners in 2024 utilizing both online and in-store channels to meet their needs. Innovative Marketing Strategies and Subscription Models Now Reshaping Consumer Purchasing Habits Capturing consumer attention in a crowded market requires sophisticated marketing and convenient purchasing models. While specific advertising budgets are proprietary, the projection of the total U.S. pet industry reaching $150.6 billion in 2024 indicates that a substantial investment in marketing is being made by all major players. One of the most successful strategies in the US pet supplement market has been the adoption of subscription services, a model that grew by an impressive 35% in 2024, with chews and bites leading the enrollment in these programs. The sheer scale of the market is evident on platforms like Amazon, which lists over 400,000 distinct dog-related products as of 2024, signaling intense competition and significant brand effort to achieve visibility. The 28% growth in online sales for chews and bites in 2024 was not accidental; it was driven by targeted digital advertising campaigns and fortified by strong social proof, reflected in an average product rating of 4.7 stars. Marketing messages are resonating deeply with owner motivations, as 78% of pet owners in 2024 are actively seeking products that they believe may extend their pet's lifespan. Customize the Data Scope to Match Your Objectives: A Dynamic Surge of Mergers and Acquisitions Is Rapidly Reshaping Competitive Frontiers The robust growth and promising future of the US pet supplement market have fueled a frenzy of corporate activity, with a clear trend toward consolidation and strategic acquisition. From January to September 2024, the pet portfolio of Health and Happiness (H&H) Group generated an impressive revenue of RMB 1.46 billion, equivalent to $201 million. Within that portfolio, the pet supplement brand Zesty Paws demonstrated strong organic performance, with sales growing by 10.6% on a like-for-like basis over the first nine months of 2024. For the full fiscal year 2024, H&H Group's pet nutrition and care business performance climbed to RMB 1.9 billion, or $272 million. This strong performance is attracting significant investment and M&A activity in the US pet supplement market In January 2024, Pet MD Brands, a subsidiary of Swedencare, acquired the premium dog treat and supplement specialist Riley's for $7.5 million. This was followed in February 2024 by Better Choice Company's announcement of its acquisition of Aimia Pet Healthco Inc. The deal-making continued throughout the year: General Mills acquired the premium pet food brand Edgard & Cooper in April; Petbuddy Group acquired Thrive Pet Foods in June; and Vetnique Labs acquired Lintbells, the maker of the highly popular YuMOVE brand of pet supplements, in July. Larger transactions are also defining the landscape; in October 2024, Bansk Group acquired PetIQ, a major manufacturer and distributor, for $1.5 billion. In November 2024, Morgan Stanley Capital Partners acquired FoodScience, a key provider of both pet and human nutritional supplements. This flurry of activity resulted in M&A volume in the pet sector reaching 60 deals year-to-date as of September 2024, with private equity add-on deals rising to 24 in the same period. The total capital invested in these M&A deals surged to $3.3 billion in the fourth quarter of 2024, signaling unshakeable investor confidence in the future of the market. U.S. Pet Supplement Market Major Players: Ark Naturals Food Science Corporation Garmon Corporation Kemin Industries, Inc. Nestlé Purina Petcare Novotech Nutraceuticals, Inc. Nutramax Laboratories, Inc. PetHonesty Virbac Zoetis Inc. Other Prominent Players Key Market Segmentation: By Pet Dog Cat By Speciality Hip & joint Digestive health Dental care Anxiety stress General health / multi-vitamin Heart & liver Skin & coat Allergies / immune support Urinary tract health By Product Type Glucosamine Probiotics Multivitamins Omega-3 Fatty Acids Others By Product Form Chewable Tablets Soft Gels Capsules Powders Liquids Others By Source Organic Conventional By End User Residential Commercial By Distribution Channel Online Company Websites E-Commerce Offline Supermarkets/ Hypermarkets Specialty Stores Others By Manufacturing Inhouse Contract/Outsource (CDMOs) Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Market to Reach $34.5 Billion by 2030 - Rise of mRNA-based Protein Replacement Therapies Strengthens Demand
The mRNA Therapeutics market is expanding due to advancements in drug development, personalized medicine, and delivery technologies. Opportunities arise from the technology's success in vaccines and potential in treating diverse diseases like cancer and genetic disorders. Challenges include regulatory and manufacturing hurdles but increased investment and innovation drive growth. mRNA Therapeutics Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics - Global Strategic Business Report" report has been added to global market for mRNA Therapeutics was estimated at US$13.3 Billion in 2024 and is projected to reach US$34.5 Billion by 2030, growing at a CAGR of 17.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The rise of mRNA therapeutics has fundamentally changed the landscape of drug development, offering a powerful platform for treating a wide range of diseases, from infectious diseases and cancer to genetic disorders and rare conditions. Unlike traditional biologics, which require complex production processes and cell culture systems, mRNA-based therapies leverage synthetic messenger RNA to instruct cells to produce therapeutic proteins directly within the body. This approach significantly accelerates drug development timelines and enhances precision in targeting disease pathways. The groundbreaking success of mRNA COVID-19 vaccines demonstrated the speed and flexibility of this technology, leading to a surge in research efforts aimed at expanding mRNA applications beyond vaccines. The ability to encode virtually any protein into an mRNA sequence has positioned this technology as a promising tool for personalized medicine, where treatments can be tailored to an individual's genetic profile. Additionally, advancements in lipid nanoparticle (LNP) delivery systems have improved the stability and targeted delivery of mRNA therapeutics, addressing previous challenges related to degradation and immunogenicity. As pharmaceutical companies and research institutions continue to invest in mRNA-based solutions, the potential for treating conditions such as autoimmune diseases, cardiovascular disorders, and neurodegenerative conditions is rapidly expanding, making mRNA therapeutics one of the most dynamic areas in modern biotechnology. What Are the Key Growth Drivers Propelling the mRNA Therapeutics Market?The growth in the mRNA therapeutics market is driven by several factors, including increasing investments in biotechnology research, expanding applications beyond vaccines, and technological advancements in mRNA delivery systems. The success of mRNA-based COVID-19 vaccines has significantly boosted funding for mRNA research, leading to an influx of clinical trials investigating mRNA therapies for cancer, metabolic diseases, and infectious diseases such as influenza, HIV, and Zika virus. The rise of personalized medicine has also accelerated interest in mRNA-based cancer vaccines, where patients receive customized treatments targeting specific tumor antigens. Additionally, the growing adoption of AI-driven drug discovery is streamlining mRNA sequence design, optimizing formulations, and reducing development timelines. The increasing demand for decentralized vaccine production and regional manufacturing hubs has spurred investments in mRNA production facilities, further supporting market expansion. The continued refinement of lipid nanoparticles and alternative delivery systems has enhanced the efficacy and safety of mRNA drugs, driving broader clinical adoption. Furthermore, government initiatives focused on pandemic preparedness and biopharmaceutical innovation are providing funding and regulatory support for mRNA therapeutics. As new indications emerge and manufacturing capabilities improve, the mRNA therapeutics market is poised for sustained growth, revolutionizing the treatment landscape for numerous diseases and positioning mRNA technology as a cornerstone of next-generation medicine. What Technological Advancements Are Enhancing the Efficacy and Delivery of mRNA Drugs?The rapid evolution of mRNA therapeutics is largely driven by advancements in formulation, delivery technologies, and sequence optimization. One of the most significant breakthroughs has been the development of chemically modified nucleotides, such as N1-methylpseudouridine, which enhance mRNA stability and reduce unwanted immune responses. Improved in vitro transcription (IVT) processes have increased mRNA yield and purity, reducing the presence of double-stranded RNA contaminants that can trigger inflammatory responses. The refinement of lipid nanoparticle (LNP) carriers has also played a crucial role in improving mRNA delivery, ensuring that the therapeutic payload reaches target tissues with high efficiency while minimizing off-target effects. Researchers are now exploring next-generation delivery systems, including polymer-based nanoparticles, exosome-derived vesicles, and peptide-based formulations, to further enhance tissue specificity and prolonged therapeutic effects. Additionally, the emergence of self-amplifying mRNA (saRNA) has opened new possibilities for lower-dose, longer-lasting treatments by enabling the production of therapeutic proteins at reduced mRNA concentrations. As artificial intelligence (AI) and machine learning are integrated into drug discovery, predictive modeling is being used to optimize mRNA sequences and delivery strategies, accelerating the development of novel mRNA-based therapies. These technological advancements are expected to expand the scope of mRNA therapeutics, unlocking new treatment paradigms across multiple disease Are Regulatory and Manufacturing Challenges Impacting the mRNA Therapeutics Market?Despite the immense potential of mRNA therapeutics, the industry faces regulatory and manufacturing challenges that must be addressed to enable widespread adoption. The highly specialized nature of mRNA production requires stringent quality control measures, particularly in raw material sourcing, in vitro transcription, and purification processes. Regulatory agencies such as the FDA and EMA have introduced new guidelines for mRNA therapeutics, focusing on product stability, immunogenicity, and manufacturing scalability. The need for Good Manufacturing Practice (GMP)-compliant production facilities has increased demand for contract development and manufacturing organizations (CDMOs) that specialize in mRNA drug production. However, the global supply chain for key components such as nucleotides, capping reagents, and lipid carriers remains vulnerable to disruptions, posing risks to large-scale manufacturing. Additionally, regulatory frameworks are still evolving for personalized mRNA therapies, such as cancer vaccines, which require customized formulations for individual patients. Another key challenge is the cost of production, as mRNA-based drugs often require cold-chain storage and sophisticated logistics for global distribution. Addressing these challenges will require continued collaboration between biotech companies, regulatory agencies, and manufacturing partners to ensure that mRNA therapeutics can be developed and distributed efficiently and safely on a global scale. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abogen Biosciences, Alnylam Pharmaceuticals, Anima Biotech, Arcturus Therapeutics Holdings Inc., BioNTech SE and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Prophylactic Products segment, which is expected to reach US$25.6 Billion by 2030 with a CAGR of a 18.3%. The Therapeutic Products segment is also set to grow at 14.2% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $3.6 Billion in 2024, and China, forecasted to grow at an impressive 22.8% CAGR to reach $7.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Scope of Study: Type (Prophylactic Products, Therapeutic Products) Application (Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application, Other Applications) End-Use (Hospitals & Clinics End-Use, Research Organizations End-Use, Other End-Uses) Key Attributes: Report Attribute Details No. of Pages 282 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $13.3 Billion Forecasted Market Value (USD) by 2030 $34.5 Billion Compound Annual Growth Rate 17.1% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns mRNA Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Increasing Investment in mRNA Technology for Therapeutic Development Drives Market Growth Surge in Global Demand for mRNA-Based Vaccines Expands Market Opportunity for mRNA Therapeutics Accelerated Research and Development in mRNA-Based Cancer Therapies Expands Market Horizons Regulatory Support and Fast-Track Approvals for mRNA Therapies Strengthen Market Confidence and Adoption Technological Advancements in mRNA Delivery Systems Propel Growth in Therapeutic Applications Rising Consumer Demand for Personalized Medicine Drives Adoption of mRNA Therapeutics in Tailored Treatment Plans The Emergence of mRNA-based Infectious Disease Treatments Spells Long-term Growth for the Therapeutics Market Increasing Use of mRNA Vaccines in Global Immunization Campaigns Accelerates Market Adoption The Shift Toward Preventive Healthcare and Proactive Disease Management Boosts Demand for mRNA Therapeutics Growing Integration of mRNA Technology into Cancer Immunotherapies Expands Market Opportunity Increasing Collaborations Between Biopharma Companies and Research Institutions Fuel mRNA Therapeutics Innovation The Global COVID-19 Pandemic Drives Significant Investment and Infrastructure Development for mRNA Therapeutics Expansion of Clinical Trials for mRNA Therapeutics in Rare and Genetic Diseases Spurs Market Potential Rising Focus on the Safety and Efficacy of mRNA-based Therapies Strengthens Consumer Confidence and Adoption The Growing Role of Artificial Intelligence and Machine Learning in mRNA Therapeutics Development Drives Innovation Expansion of Manufacturing Capabilities for mRNA-based Drugs Increases Market Accessibility and Scalability Increasing Global Health Initiatives and Public-Private Partnerships Accelerates Demand for mRNA Therapeutics The Rise of mRNA-based Protein Replacement Therapies Strengthens Market Demand for mRNA in Genetic Disorders Regulatory and Ethical Issues Surrounding mRNA Technology Drive Innovation in Safety Protocols and Guidelines Increasing Interest in mRNA as a Platform for Targeted Therapies Expands Addressable Market Opportunity for Therapeutic Products FOCUS ON SELECT PLAYERS | Some of the 48 Companies Featured in This Report Abogen Biosciences Alnylam Pharmaceuticals Anima Biotech Arcturus Therapeutics Holdings Inc. BioNTech SE Comanche Biopharma CureVac N.V. eTheRNA Immunotherapies NV Ethris GmbH EXACIS Biotherapeutics Gritstone bio, Inc. HC Bioscience Inflammatix, Inc. Ionis Pharmaceuticals Moderna, Inc. Nutcracker Therapeutics Orna Therapeutics ReCode Therapeutics Strand Therapeutics Translate Bio (Acquired by Sanofi) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment mRNA Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
